Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
21.48
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...
Via
Benzinga
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
January 25, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses
January 24, 2022
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying...
Via
Benzinga
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
January 24, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 21, 2022
From
Arcturus Therapeutics
Via
Business Wire
65 Biggest Movers From Yesterday
January 19, 2022
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 18, 2022
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of...
Via
Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 17, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
58 Biggest Movers From Yesterday
December 17, 2021
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price...
Via
Benzinga
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
December 16, 2021
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 16, 2021
Gainers Calliditas Therapeutics (NASDAQ:CALT...
Via
Benzinga
31 Stocks Moving In Thursday's Mid-Day Session
December 16, 2021
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce...
Via
Benzinga
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
December 16, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
December 13, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
November 08, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 25, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Leadership Appointments
October 21, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
92 Biggest Movers From Friday
November 08, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...
Via
Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
October 12, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
October 06, 2021
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...
Via
Benzinga
Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83
September 29, 2021
Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level.
Via
Investor's Business Daily
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
September 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial
September 22, 2021
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...
Via
Benzinga
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Earnings Perspective: Return On Capital Employed
September 15, 2021
According to Benzinga Pro data, during Q2, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.00 million. Earnings were up 6.84%, but Arcturus Therapeutics still reported an...
Via
Benzinga
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
September 08, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.